The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond

Current Opinion in Pharmacology

Volumn 20, Issue , 2015, Pages 109-115

  Balu, Darrick T ^a,b   Coyle, Joseph T ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID; BITOPERIN; CYCLOSERINE; DEXTRO ALANINE; DEXTRO AMINO ACID OXIDASE; DEXTRO SERINE; GLYCINE; GLYCINE RECEPTOR ANTAGONIST; GLYCINE TRANSPORTER; GLYCINE TRANSPORTER 1; GLYCINE TRANSPORTER 1 ANTAGONIST; GLYCINE TRANSPORTER 2; KYNURENIC ACID; KYNURENINE AMINOTRANSFERASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PHOSPHOGLYCERATE DEHYDROGENASE; PLACEBO; RACEMASE; SARCOSINE; UNCLASSIFIED DRUG; DOPAMINE; SERINE;

ANHEDONIA; ARTICLE; ATAXIA; COGNITION; COGNITIVE DEFECT; COPY NUMBER VARIATION; DELUSION; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; GABAERGIC SYSTEM; HALLUCINATION; HUMAN; HYPOACTIVITY; INTERNEURON; MENTAL DISEASE; NEGATIVE SYNDROME; NERVE CELL PLASTICITY; POSTSYNAPTIC DENSITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TARGETING; RESPIRATORY FAILURE; SCHIZOPHRENIA; SYMPTOMATOLOGY; ANIMAL; COGNITION DISORDERS; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; SYNAPSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOPAMINE; GLYCINE; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SERINE; SYNAPSES;

EID: 84919608198     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.12.004     Document Type: Review

References (63)

1. Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, Kieseppa T et al.: Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007, 64:19-28.
2. DeLisi LE, Szulc KU, Bertisch HC, Majcher M, Brown K: Understanding structural brain changes in schizophrenia. Dialogues Clin Neurosci 2006, 8:71-78.
3. Schizophrenia Working Group of the Psychiatric Genomics C: Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014, 511:421-427.
4. Bergeron R, Meyer TM, Coyle JT, Greene RW: Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A 1998, 95:15730-15734.
5. Wolosker H, Blackshaw S, Snyder SH: Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci U S A 1999, 96:13409-13414.
6. Schell MJ, Molliver ME, Snyder SH: D-Serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci U S A 1995, 92:3948-3952.
7. Hashimoto A, Nishikawa T, Oka T, Takahashi K: Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging. J Neurochem 1993, 60:783-786.
8. Papouin T, Ladepeche L, Ruel J, Sacchi S, Labasque M, Hanini M, Groc L, Pollegioni L, Mothet JP, Oliet SH: Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012, 150:633-646.
9. Rosenberg D, Artoul S, Segal AC, Kolodney G, Radzishevsky I, Dikopoltsev E, Foltyn VN, Inoue R, Mori H, Billard JM et al.: Neuronal D-serine and glycine release via the Asc-1 transporter regulates NMDA receptor-dependent synaptic activity. J Neurosci 2013, 33:3533-3544.
10. Basu AC, Tsai GE, Ma CL, Ehmsen JT, Mustafa AK, Han L, Jiang ZI, Benneyworth MA, Froimowitz MP, Lange N et al.: Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry 2009, 14:719-727.
11. Ehmsen JT, Ma TM, Sason H, Rosenberg D, Ogo T, Furuya S, Snyder SH, Wolosker H: D-Serine in glia and neurons derives from 3-phosphoglycerate dehydrogenase. J Neurosci 2013, 33:12464-12469.
12. Yang JH, Wada A, Yoshida K, Miyoshi Y, Sayano T, Esaki K, Kinoshita MO, Tomonaga S, Azuma N, Watanabe M et al.: Brain-specific Phgdh deletion reveals a pivotal role for L-serine biosynthesis in controlling the level of D-serine, an N-methyl-Daspartate receptor co-agonist, in adult brain. J Biol Chem 2010, 285:41380-41390.
13. Mothet JP, Pollegioni L, Ouanounou G, Martineau M, Fossier P, Baux G: Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter D-serine. Proc Natl Acad Sci U S A 2005, 102:5606-5611.
14. Miya K, Inoue R, Takata Y, Abe M, Natsume R, Sakimura K, Hongou K, Miyawaki T, Mori H: Serine racemase is predominantly localized in neurons in mouse brain. J Comp Neurol 2008, 510:641-654.
15. Benneyworth MA, Li Y, Basu AC, Bolshakov VY, Coyle JT: Cell selective conditional null mutations of serine racemase demonstrate a predominate localization in cortical glutamatergic neurons. Cell Mol Neurobiol 2012, 32:613-624.
16. Balu DT, Takagi S, Puhl MD, Benneyworth MA, Coyle JT: D-Serine and serine racemase are localized to neurons in the adult mouse and human forebrain. Cell Mol Neurobiol 2014, 34:419-435.
17. Fossat P, Turpin FR, Sacchi S, Dulong J, Shi T, Rivet JM, Sweedler JV, Pollegioni L, Millan MJ, Oliet SH et al.: Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex. Cereb Cortex 2012, 22:595-606.
18. Martineau M, Shi T, Puyal J, Knolhoff AM, Dulong J, Gasnier B, Klingauf J, Sweedler JV, Jahn R, Mothet JP: Storage and uptake of D-serine into astrocytic synaptic-like vesicles specify gliotransmission. J Neurosci 2013, 33:3413-3423.
19. Betz H, Gomeza J, Armsen W, Scholze P, Eulenburg V: Glycine transporters: essential regulators of synaptic transmission. Biochem Soc Trans 2006, 34:55-58.
20. Zafra F, Gomeza J, Olivares L, Aragon C, Gimenez C: Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur J Neurosci 1995, 7:1342-1352.
21. Cubelos B, Gimenez C, Zafra F: Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 2005, 15:448-459.
22. Kessler M, Terramani T, Lynch G, Baudry M: A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 1989, 52:1319-1328.
23. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX: The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 2001, 21:7463-7473.
24. Lugo-Huitron R, Blanco-Ayala T, Ugalde-Muniz P, Carrillo-Mora P, Pedraza-Chaverri J, Silva-Adaya D, Maldonado PD, Torres I, Pinzon E, Ortiz-Islas E et al.: On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol 2011, 33:538-547.
25. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
26. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA: Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001, 25:455-467.
27. Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D et al.: Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007, 61:25-36.
28. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R: Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011, 10:63-74.
29. Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein HG, Vielhaber S, Kastner A, Skalej M, Jordan W, Schiltz K et al.: Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry 2013, 70:271-278.
30. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, Tanzi RE, Bertram L: Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008, 40:827-834.
31. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, Georgieva L, Rees E, Palta P, Ruderfer DM et al.: De novo mutations in schizophrenia implicate synaptic networks. Nature 2014, 506:178-184.
32. Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D, Moran J, Chambert K, Toncheva D, Georgieva L et al.: De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 2012, 17:142-153.
33. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, O'Dushlaine C, Chambert K, Bergen SE, Kahler A et al.: A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014, 506:185-190.
34. Weickert CS, Fung SJ, Catts VS, Schofield PR, Allen KM, Moore LT, Newell KA, Pellen D, Huang XF, Catts SV et al.: Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol Psychiatry 2013, 18:1185-1192.
35. Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H, Agam G: A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 2007, 90:41-51.
36. Goltsov AY, Loseva JG, Andreeva TV, Grigorenko AP, Abramova LI, Kaleda VG, Orlova VA, Moliaka YK, Rogaev EI: Polymorphism in the 5′-promoter region of serine racemase gene in schizophrenia. Mol Psychiatry 2006, 11:325-326.
37. Labrie V, Wang W, Barger SW, Baker GB, Roder JC: Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice. Genes Brain Behav 2009, 9:11-25.
38. Morita Y, Ujike H, Tanaka Y, Otani K, Kishimoto M, Morio A, Kotaka T, Okahisa Y, Matsushita M, Morikawa A et al.: A genetic variant of the serine racemase gene is associated with schizophrenia. Biol Psychiatry 2007, 61:1200-1203.
39. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M: Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:767-769.
40. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G: Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001, 313:96-98.
41. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC: Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001, 50:521-530.
42. Balu DT, Li Y, Puhl MD, Benneyworth MA, Basu AC, Takagi S, Bolshakov VY, Coyle JT: Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci U S A 2013, 110:E2400-E2409.
43. DeVito LM, Balu DT, Kanter BR, Lykken C, Basu AC, Coyle JT, Eichenbaum H: Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes Brain Behav 2011, 10:210-222.
44. Carlson GC, Talbot K, Halene TB, Gandal MJ, Kazi HA, Schlosser L, Phung QH, Gur RE, Arnold SE, Siegel SJ: Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. Proc Natl Acad Sci U S A 2011, 108:E962-E970.
45. Karlsgodt KH, Robleto K, Trantham-Davidson H, Jairl C, Cannon TD, Lavin A, Jentsch JD: Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance. Biol Psychiatry 2011, 69:28-34.
46. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan EM, Nakazawa K: Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2009, 13:76-83.
47. Goff DC, Tsai G, Manoach DS, Coyle JT: Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995, 152:1213-1215.
48. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH: Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 1994, 257:7-12.
49. Tsai GE, Lin PY: Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010, 16:522-537.
50. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT: The Cognitive Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007, 164:1593-1602.
51. Coyle JT, Tsai G: The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 2004, 174:32-38.
52. Li Y, Sacchi S, Pollegioni L, Basu AC, Coyle JT, Bolshakov VY: Identity of endogenous NMDAR glycine site agonist in amygdala is determined by synaptic activity level. Nat Commun 2013, 4:1760.
53. Verrall L, Burnet PW, Betts JF, Harrison PJ: The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. Mol Psychiatry 2010, 15:122-137.
54. Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE: Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 2013, 70:1267-1275.
55. Kozak R, Campbell BM, Strick CA, Horner W, Hoffmann WE, Kiss T, Chapin DS, McGinnis D, Abbott AL, Roberts BM et al.: Reduction of brain kynurenic acid improves cognitive function. J Neurosci 2014, 34:10592-10602.
56. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ: Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012, 13:465-477.
57. Herman EJ, Bubser M, Conn PJ, Jones CK: Metabotropic glutamate receptors for new treatments in schizophrenia. Handb Exp Pharmacol 2012, 29:7-365.
58. Albuquerque EX, Schwarcz R: Kynurenic acid as an antagonist of alpha7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochem Pharmacol 2013, 85:1027-1032.
59. Paul SM, Doherty JJ, Robichaud AJ, Belfort GM, Chow BY, Hammond RS, Crawford DC, Linsenbardt AJ, Shu HJ, Izumi Y et al.: The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J Neurosci 2013, 33:17290-17300.
60. Jones CK, Byun N, Bubser M: Muscarinic nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 2012, 37:16-42.
61. Lin EI, Jeyifous O, Green WN: CASK regulates SAP97 conformation and its interactions with AMPA and NMDA receptors. J Neurosci 2013, 33:12067-12076.
62. Wang XQ, Deriy LV, Foss S, Huang P, Lamb FS, Kaetzel MA, Bindokas V, Marks JD, Nelson DJ: CLC-3 channels modulate excitatory synaptic transmission in hippocampal neurons. Neuron 2006, 52:321-333.
63. Guzman RE, Alekov AK, Filippov M, Hegermann J, Fahlke C: Involvement of ClC-3 chloride/proton exchangers in controlling glutamatergic synaptic strength in cultured hippocampal neurons. Front Cell Neurosci 2014, 8:143.